Insider Transactions in Q3 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,796
-0.38%
|
$77,228
$43.02 P/Share
|
|
Sep 11
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
553
-0.33%
|
$23,779
$43.02 P/Share
|
|
Sep 11
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
659
-1.13%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
659
-0.72%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
586
-0.3%
|
$25,198
$43.02 P/Share
|
|
Sep 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.0%
|
$1,290,000
$43.87 P/Share
|
|
Sep 10
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,941
+1.45%
|
$194,233
$13.12 P/Share
|
|
Sep 08
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.48%
|
$550,000
$44.53 P/Share
|
|
Sep 08
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.28%
|
$225,000
$18.6 P/Share
|
|
Sep 02
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.01%
|
$575,000
$46.83 P/Share
|
|
Sep 02
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.62%
|
$262,500
$21.1 P/Share
|
|
Aug 15
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+8.98%
|
$49,400
$19.62 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.99%
|
$600,000
$48.02 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.62%
|
$262,500
$21.1 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
SELL
Open market or private sale
|
Direct |
3,000
-24.2%
|
$141,000
$47.46 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+19.48%
|
$21,000
$7.01 P/Share
|
|
Aug 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.95%
|
$1,440,000
$48.79 P/Share
|
|
Aug 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.54%
|
$612,500
$49.28 P/Share
|
|
Aug 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.99%
|
$530,000
$53.17 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.97%
|
$190,000
$19.87 P/Share
|
|
Jul 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.76%
|
$1,530,000
$51.15 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.34%
|
$637,500
$51.85 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 01
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-6.27%
|
$104,000
$52.88 P/Share
|